Effects of Adolescent THC Exposure on the Prefrontal GABAergic System: Implications for Schizophrenia-Related Psychopathology

Frontiers in Psychiatry
Justine RenardSteven R Laviolette

Abstract

Marijuana is the most commonly used drug of abuse among adolescents. Considerable clinical evidence supports the hypothesis that adolescent neurodevelopmental exposure to high levels of the principal psychoactive component in marijuana, -delta-9-tetrahydrocanabinol (THC), is associated with a high risk of developing psychiatric diseases, such as schizophrenia later in life. This marijuana-associated risk is believed to be related to increasing levels of THC found within commonly used marijuana strains. Adolescence is a highly vulnerable period for the development of the brain, where the inhibitory GABAergic system plays a pivotal role in the maturation of regulatory control mechanisms in the central nervous system (CNS). Specifically, adolescent neurodevelopment represents a critical period wherein regulatory connectivity between higher-order cortical regions and sub-cortical emotional processing circuits such as the mesolimbic dopamine (DA) system is established. Emerging preclinical evidence demonstrates that adolescent exposure to THC selectively targets schizophrenia-related molecular and neuropharmacological signaling pathways in both cortical and sub-cortical regions, including the prefrontal cortex (PFC) and mesolimbic D...Continue Reading

References

Jan 1, 1992·Clinical Neuropharmacology·A Delini-StulaN Neumann
Jan 1, 1991·Psychopharmacology·A W ZuardiJ M Cunha
Mar 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·M HerkenhamK C Rice
Apr 20, 1982·The Journal of Comparative Neurology·A PetersC E Ribak
Jul 1, 1996·Journal of Psychiatric Research·A Delini-Stula, D Berdah-Tordjman
Jun 10, 1997·Proceedings of the National Academy of Sciences of the United States of America·H AsadaK Obata
Jul 1, 1997·The American Journal of Psychiatry·T U WooD A Lewis
Jun 6, 1998·Proceedings of the National Academy of Sciences of the United States of America·T U WooD A Lewis
Dec 9, 1998·Proceedings of the National Academy of Sciences of the United States of America·M M HuntsmanE G Jones
Jun 11, 1999·Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology·F AokiG A Ojemann
Jul 9, 1999·Neurochemistry International·W SieghartD Adamiker
Sep 24, 1999·Nature Neuroscience·J N GieddJ L Rapoport
May 19, 2000·Neuroscience and Biobehavioral Reviews·L P Spear
Aug 3, 2001·Nature Reviews. Neuroscience·E Salinas, T J Sejnowski
Sep 5, 2001·The Journal of Physiology·D EngelA Draguhn
Oct 12, 2001·Schizophrenia Research·N KozlovskyG Agam
Oct 30, 2001·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·C L HartM W Fischman
Jan 22, 2002·Nature Neuroscience·Christos ConstantinidisPatricia S Goldman-Rakic
Oct 5, 2002·Schizophrenia Research·Marquis P VawterWilliam J Freed
Nov 26, 2002·BMJ : British Medical Journal·Louise ArseneaultTerrie E Moffitt
Jan 16, 2003·Physiology & Behavior·David W Volk, David A Lewis
Feb 21, 2003·Nature·Thomas KlausbergerPeter Somogyi
Apr 16, 2003·International Journal of Psychophysiology : Official Journal of the International Organization of Psychophysiology·J A González-HernándezP Figueredo-Rodríguez
May 7, 2003·Neuroscience and Biobehavioral Reviews·Susan L Andersen
Jun 5, 2003·The American Journal of Psychiatry·R Andrew ChambersMarc N Potenza
Jul 31, 2003·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Miriam Schneider, Michael Koch
Nov 20, 2003·Trends in Neurosciences·Miles A Whittington, Roger D Traub
Feb 3, 2004·The British Journal of Psychiatry : the Journal of Mental Science·Louise ArseneaultRobin M Murray
Mar 30, 2004·Trends in Neurosciences·György BuzsákiXiao-Jing Wang
May 19, 2004·Proceedings of the National Academy of Sciences of the United States of America·Nitin GogtayPaul M Thompson
May 26, 2004·Life Sciences·Viviane M C GuimarãesFrancisco S Guimarães
Jun 3, 2004·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Deepak Cyril D'SouzaJohn Harrison Krystal

❮ Previous
Next ❯

Citations

Nov 18, 2018·European Psychiatry : the Journal of the Association of European Psychiatrists·Andre F CarvalhoAi Koyanagi
Jan 10, 2020·Proceedings of the National Academy of Sciences of the United States of America·Helen Shen
Mar 30, 2021·Current Addiction Reports·Punitha Subramaniam, Deborah Yurgelun-Todd
Aug 14, 2020·Progress in Neuro-psychopharmacology & Biological Psychiatry·Sierra J Stringfield, Mary M Torregrossa

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

Addison Disease

Addison's disease, also known as primary adrenal insufficiency and hypocortisolism, is a long-term endocrine disorder in which the adrenal glands do not produce enough steroid hormones. Discover the latest research on Addison's disease here.